Marc Jarvis

Trainee Patent Attorney

Marc graduated with a BSc (Hons) in Cell Biology with industrial experience from the University of Manchester. His industrial year was in the Oncology department at Boehringer Ingelheim in Vienna, Austria where he worked on a novel Aurora B kinase inhibitor.
 

Marc undertook his PhD research in the laboratory of Jan-Michael Peters at the Research Institute of Molecular Pathology, Vienna, Austria, focusing on the 1.5 MDa E3 ubiquitin ligase, the Anaphase Promoting Complex. In particular, his research focused on how substrates for destruction are structurally recognised and how the E2 enzyme UBE2S builds ubiquitin chains. Consequently, he has knowledge of biochemistry, cell biology, molecular biology, structural biology and CRISPR/Cas9 technology. As part of his PhD, Marc also spent extended periods of time in the laboratory of Brenda A. Schulman at the Howard Hughes Medical Institute, St Jude Children’s Research Hospital, Memphis, USA.
 

Marc joined Kilburn & Strode in September 2016 as a Technical Assistant and is currently training to become a European and UK patent attorney in the Life Sciences and Chemistry group.
 

Qualifications

PhD Molecular Life Sciences – Research Institute for Molecular Pathology, Vienna, Austria (2014)

BSc Cell Biology (Hons) with Industrial Experience – The University of Manchester (2010)
 

Memberships

Chartered Institute of Patent Attorneys (CIPA) - student member
The Institute of Professional Representatives before the European Patent Office (EPI) - student member
 

Selected Publications

Dual RING E3 Architectures Regulate Multiubiquitination and Ubiquitin Chain Elongation by APC/C, Cell, 2016. 165 (6). 1440-53

Mechanism of APC/CCDC20 activation by mitotic phosphorylation, Proceedings of the National Academy of Sciences of the United States of America, 2016. 113 (19). E2570-2578.

Measuring APC/C-dependent ubiquitylation in vitro, Methods in Molecular Biology, 2016. 1342. 287-303.

ProteoPlex: stability optimization of macromolecular complexes by sparse-matrix screening of chemical space, Nature Methods, 2015. 12 (9). 859-865.

Mechanism of polyubiquitination by human Anaphase-Promoting Complex: RING repurposing for ubiquitin chain assembly, Molecular Cell, 2014. 56 (2). 246–260.

Electron microscopy structure of human APC/CCDH1-EMI1 reveals multimodal mechanism of E3 ligase shutdown, Nature Structural & Molecular Biology, 2013. 20 (7). 827–835.

APC15 mediates CDC20 autoubiquitylation by APC/C-MCC and disassembly of the mitotic checkpoint complex, Nature Structural & Molecular Biology, 2012. 19 (11). 1116–1123.

Molecular and cellular pharmacology of BI 811283, a potent inhibitor of Aurora B kinase, Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, 17-21 April 2010, Washington DC, USA. AACR 2010 abstract number: 1080.

Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis, Journal of Clinical Oncology, 2010. 28. Abstract number: e13632.

  • Biotechnology
  • Biologics
  • Healthcare
  • Pharmaceuticals
  • Patents

The life sciences and chemistry team regularly contributes thoughts and insights to our future thinking.

Read here

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept